Month: December 2025

China’s AI-driven healthcare sector has moved beyond experimentation into scaled, real-world deployment. A new wave of representative companies is reshaping the industry from multiple angles—clinical diagnosis, drug discovery, healthcare services, and data infrastructure. Below are eight standout players and how they are driving change.

1. Yidu Tech (医渡科技) – The Healthcare Big Data Infrastructure Specialist

• Stock code: HKEX 02558.HK | Market cap: ~HKD 4B | FY2024 revenue: RMB 820M
• Core strength: Medical data intelligence. Yidu’s key capability is converting unstructured hospital data into structured, research- and clinical-ready datasets—effectively acting as the industry’s “data refinery.”

How it drives transformation:

• Empowering research: Provides hospitals, pharma companies, and governments with disease insights and analytics platforms to accelerate clinical research and R&D.
• Supporting public health: Helps build regional health data platforms for epidemic monitoring, disease prevention/control, and public health decision-making.

In one sentence: Not a “doctor” that treats patients, but the infrastructure provider supplying the “oil” (data) and “refinery” (analytics) that power the entire healthcare system.

2. United Imaging Healthcare (联影医疗)- The Full-Stack AI + Medical Hardware Champion

• Stock code: STAR Market 688271.SH | Market cap: ~RMB 120B | 2024 revenue: RMB 10.3B
• Core strength: Deep integration of hardware + AI. As a leading medical imaging equipment maker, its AI algorithms are embedded directly into CT/MRI devices, enabling intelligence at the source.

How it drives transformation:

• Scan-to-insight: AI assists lesion detection, segmentation, and preliminary diagnosis at the moment of imaging*, improving speed and accuracy.
• End-to-end solutions: Covers a full workflow from screening and diagnosis to treatment and follow-up.

In one sentence: It makes expensive medical equipment not only “see clearly,” but also “understand what it sees.”

3. Infervision (推想科技) – Pioneer of AI Imaging Diagnostics and a Globalization Benchmark

• Valuation: > USD 1B
• Core strength: One of China’s earliest AI medical imaging companies and among the most globalized—products are cleared/approved across China, the US, Europe, and Japan.

How it drives transformation:

• A high-efficiency assistant for radiologists: Automates detection of lung nodules, pneumonia, intracranial hemorrhage, and more, easing workload and improving throughput.
• Proof of global competitiveness: Its international certification path demonstrates that Chinese AI healthcare products can meet top global standards.

In one sentence: A leading example of Chinese AI healthcare going global—and winning on quality.

4. iFLYTEK (科大讯飞) – A Platform Giant Enabling Healthcare at Scale

• Stock code: SZSE 002230.SZ | Market cap: ~RMB 110B | 2025 H1 revenue: RMB 17.0B
• Core strength: China’s “national team” in speech AI, expanding from general AI capabilities into verticals like healthcare via a platform strategy.

How it drives transformation:

• AI clinical assistant (primary care): Conversational AI helps doctors generate medical records and suggests diagnostic/treatment pathways—raising the quality of 基层医疗 (primary care) and easing resource imbalance.
• Hospital digitalization: Voice EMR, smart triage, and service robots to improve patient experience and operational efficiency.

In one sentence: iFLYTEK goes “from general to vertical,” using a strong AI platform to enable multiple healthcare workflows.

5. Unisound (云知声) – A Hardcore Specialist for Regulated Clinical Workflows

• Stock code: HKEX 09678.HK | Market cap: HKD 28.5B
• AI healthcare revenue: 2025 H1 smart healthcare revenue RMB 70M; average contract value RMB 1.013M, +116.2% YoY
• Core strength: Deep vertical focus + high compliance barriers. Products like clinical documentation quality control require Class III medical device registration, creating strong defensibility.

How it drives transformation:

• Reshaping clinical workflows: Voice EMR changes documentation input; “medical record quality control” acts like a tireless senior physician to audit record quality and reduce safety risks.
• Serving the payer side: Intelligent medical insurance audit systems help payers reduce improper claims—demonstrating measurable economic value of AI.

In one sentence: Unisound is “deep and specialized,” building high-barrier products that directly reshape core clinical processes.

6. Insilico Medicine (英矽智能) – A Leader in AI-Native Drug Discovery

• Stock code: HKEX 03696.HK | Market cap: ~HKD 13.4B | 2025 H1 revenue: HKD 200M
• Core strength: A global unicorn focused on using generative AI and related methods to improve drug discovery efficiency and success rates.

How it drives transformation:

• From years to months: AI platforms can compress target discovery and early-stage discovery timelines dramatically.
• Milestone progress: Its AI-discovered anti-fibrotic drug has entered late-stage clinical trials, widely viewed as a landmark case.

In one sentence: It tackles pharma’s biggest pain point—the “rule of 10s” (often ~10 years, ~$1B)—with AI-first R&D.

7. Medlinker (医联) – Serious Care via Internet Hospital + AI

• Valuation: RMB 28.5B | Backers include Tencent, Sequoia China, Sino Biopharmaceutical (01177.HK), etc.
• Core strength: A representative internet-hospital model focused on serious diseases and chronic disease management—using AI to support doctors and provide continuous patient management.

How it drives transformation:

• AI doctor assistant: Developed a medical AI model MedGPT to support diagnosis and treatment planning via multimodal analysis.
• New care model: Builds an online closed-loop across prevention, diagnosis, treatment, and rehabilitation—especially for chronic care.

In one sentence: It aims to rebuild chronic and serious care pathways through “internet hospital + AI.”

8. XtalPi (晶泰科技)- A Global Leader in AI Drug R&D Platforms

• Stock code: HKEX 02161.HK | Market cap: ~HKD 41.8B
• 2025 H1 revenue: RMB 567M, +403.8% YoY (mainly AI drug R&D services and collaborations)
• Core strength: “Quantum physics + AI + robotic automation.” XtalPi combines quantum-based computation, AI, and cloud robotics to build a distinctive closed-loop, wet-lab + dry-lab platform.
  • Platform company positioning: “AI for Science” platform rather than a traditional pharma company; claims 200+ domain-specific AI models to boost the speed and success of scientific discovery.
  • Global footprint & high barriers: Deep collaboration with global pharma leaders (e.g., Pfizer, J&J), creating strong technical and reputational moats.

How it drives transformation

• Changing the drug discovery paradigm: Compresses preclinical R&D cycles from ~5 years to months, directly targeting the industry’s “rule of 10s.”
• Creating major commercial value: In 2025, signed a pipeline collaboration with DoveTree with a total potential value of USD 5.99B, cited as one of the largest deals in the global AI drug discovery space.
• From tech to clinical validation: A targeted therapy for diffuse gastric cancer in partnership with another biotech received US FDA Orphan Drug Designation and Fast Track—a marker that AI-enabled drugs are moving into late-stage clinical value validation.

In one sentence: XtalPi is not just an AI drug discovery service provider—it’s a risk-sharing, value-sharing platform demonstrating that AI can produce real drugs and real outcomes.